Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Ramesh Itteboina, Srilata Ballu, Sree Kanth Sivan & Vijjulatha Manga. (2018) Molecular docking, 3D-QSAR, molecular dynamics, synthesis and anticancer activity of tyrosine kinase 2 (TYK 2) inhibitors. Journal of Receptors and Signal Transduction 38:5-6, pages 462-474.
Read now
Read now
Ramesh Itteboina, Srilata Ballu, Sree Kanth Sivan & Vijjulatha Manga. (2017) Molecular modeling-driven approach for identification of Janus kinase 1 inhibitors through 3D-QSAR, docking and molecular dynamics simulations. Journal of Receptors and Signal Transduction 37:5, pages 453-469.
Read now
Read now
Peter Norman. (2014) Evaluation of WO2013125543, WO2013146963 and EP2634185: the first Tyk2 inhibitors from Takeda and Sareum. Expert Opinion on Therapeutic Patents 24:3, pages 361-368.
Read now
Read now
Brian W Dymock & Cheng Shang See. (2013) Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 – 2012. Expert Opinion on Therapeutic Patents 23:4, pages 449-501.
Read now
Read now
Peter Norman. (2012) Selective JAK1 inhibitor and selective Tyk2 inhibitor patents. Expert Opinion on Therapeutic Patents 22:10, pages 1233-1249.
Read now
Read now
Articles from other publishers (26)
Nguyen Thi Mai, Ngo Thi Lan, Thien Y. Vu, Nguyen Thanh Tung & Huong Thi Thu Phung. (2022) A computationally affordable approach for accurate prediction of the binding affinity of JAK2 inhibitors. Journal of Molecular Modeling 28:6.
Crossref
Crossref
Syeda Rehana Zia. (2021) Role of water in the determination of protonation states of titratable residues. Journal of Molecular Modeling 27:2.
Crossref
Crossref
Emad M. Gad, Mohamed S. Nafie, Elsayed H. Eltamany, Magdy S. A. G. Hammad, Assem Barakat & Ahmed T. A. Boraei. (2020) Discovery of New Apoptosis-Inducing Agents for Breast Cancer Based on Ethyl 2-Amino-4,5,6,7-Tetra Hydrobenzo[b]Thiophene-3-Carboxylate: Synthesis, In Vitro, and In Vivo Activity Evaluation. Molecules 25:11, pages 2523.
Crossref
Crossref
Seketoulie Keretsu, Swapnil Pandurang Bhujbal & Seung Joo Cho. (2020)
Computational Study of Pyrimidin‐2‐Aminopyrazol‐Hydroxamate‐based
JAK2
Inhibitors for the Treatment of Myeloproliferative Neoplasms
. Bulletin of the Korean Chemical Society 41:5, pages 542-551.
Crossref
Crossref
Addila Abu Bakar, Muhammad Akhtar, Norlaily Mohd Ali, Swee Yeap, Ching Quah, Wan-Sin Loh, Noorjahan Alitheen, Seema Zareen, Zaheer Ul-Haq & Syed Shah. (2018) Design, Synthesis and Docking Studies of Flavokawain B Type Chalcones and Their Cytotoxic Effects on MCF-7 and MDA-MB-231 Cell Lines. Molecules 23:3, pages 616.
Crossref
Crossref
Hiroaki Yamagishi, Takayuki Inoue, Yutaka Nakajima, Jun Maeda, Hiroaki Tominaga, Hiroyuki Usuda, Takeshi Hondo, Ayako Moritomo, Fumihiro Nakamori, Misato Ito, Koji Nakamura, Hiroki Morio, Yasuyuki Higashi, Masamichi Inami & Shohei Shirakami. (2017) Discovery of tricyclic dipyrrolopyridine derivatives as novel JAK inhibitors. Bioorganic & Medicinal Chemistry 25:20, pages 5311-5326.
Crossref
Crossref
Tingfang Wang, Xiaofei Liu, Meixi Hao, Jianan Qiao, Caoyun Ju, Lingjing Xue & Can Zhang. (2016) Design, synthesis and evaluation of pyrrolo[2,3-d]pyrimidine-phenylamide hybrids as potent Janus kinase 2 inhibitors. Bioorganic & Medicinal Chemistry Letters 26:12, pages 2936-2941.
Crossref
Crossref
Hiroaki Yamagishi, Shohei Shirakami, Yutaka Nakajima, Akira Tanaka, Fumie Takahashi, Hisao Hamaguchi, Keiko Hatanaka, Ayako Moritomo, Masamichi Inami, Yasuyuki Higashi & Takayuki Inoue. (2015) Discovery of 3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-2(1H)-one derivatives as novel JAK inhibitors. Bioorganic & Medicinal Chemistry 23:15, pages 4846-4859.
Crossref
Crossref
Maria Gabriella Brasca, Paola Gnocchi, Marcella Nesi, Nadia Amboldi, Nilla Avanzi, Jay Bertrand, Simona Bindi, Giulia Canevari, Daniele Casero, Marina Ciomei, Nicoletta Colombo, Sabrina Cribioli, Gabriele Fachin, Eduard R. Felder, Arturo Galvani, Antonella Isacchi, Ilaria Motto, Achille Panzeri & Daniele Donati. (2015) Novel pyrrole carboxamide inhibitors of JAK2 as potential treatment of myeloproliferative disorders. Bioorganic & Medicinal Chemistry 23:10, pages 2387-2407.
Crossref
Crossref
Maria Gabriella Brasca, Marcella Nesi, Nilla Avanzi, Dario Ballinari, Tiziano Bandiera, Jay Bertrand, Simona Bindi, Giulia Canevari, Davide Carenzi, Daniele Casero, Lucio Ceriani, Marina Ciomei, Alessandra Cirla, Maristella Colombo, Sabrina Cribioli, Cinzia Cristiani, Franco Della Vedova, Gabriele Fachin, Marina Fasolini, Eduard R. Felder, Arturo Galvani, Antonella Isacchi, Danilo Mirizzi, Ilaria Motto, Achille Panzeri, Enrico Pesenti, Paola Vianello, Paola Gnocchi & Daniele Donati. (2014) Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors. Bioorganic & Medicinal Chemistry 22:17, pages 4998-5012.
Crossref
Crossref
Brian W Dymock, Eugene Guorong Yang, Yuyi Chu-Farseeva & Lianbin Yao. (2014) Selective JAK inhibitors. Future Medicinal Chemistry 6:12, pages 1439-1471.
Crossref
Crossref
Qibin Su, Stephanos Ioannidis, Claudio Chuaqui, Lynsie Almeida, Marat Alimzhanov, Geraldine Bebernitz, Kirsten Bell, Michael Block, Tina Howard, Shan Huang, Dennis Huszar, Jon A. Read, Caroline Rivard Costa, Jie Shi, Mei Su, Minwei Ye & Michael Zinda. (2013)
Discovery of 1-Methyl-1
H
-imidazole Derivatives as Potent Jak2 Inhibitors
. Journal of Medicinal Chemistry 57:1, pages 144-158.
Crossref
Crossref
Min-Yi Li, Yan Tian, Li Shen, Ralf Buettner, Hong-Zhi Li, Lucy Liu, Yate-Ching Yuan, Qiang Xiao, Jun Wu & Richard Jove. (2013) 3-O-methylthespesilactam, a new small-molecule anticancer pan-JAK inhibitor against A2058 human melanoma cells. Biochemical Pharmacology 86:10, pages 1411-1418.
Crossref
Crossref
Michael Siu, Richard Pastor, Wendy Liu, Kathy Barrett, Megan Berry, Wade S. Blair, Christine Chang, Jacob Z. Chen, Charles Eigenbrot, Nico Ghilardi, Paul Gibbons, Haiying He, Christopher A. Hurley, Jane R. Kenny, S. Cyrus Khojasteh, Hoa Le, Leslie Lee, Joseph P. Lyssikatos, Steve Magnuson, Rebecca Pulk, Vickie Tsui, Mark Ultsch, Yisong Xiao, Bing-yan Zhu & Deepak Sampath. (2013) 2-Amino-[1,2,4]triazolo[1,5-a]pyridines as JAK2 inhibitors. Bioorganic & Medicinal Chemistry Letters 23:17, pages 5014-5021.
Crossref
Crossref
Christopher A. Hurley, Wade S. Blair, Richard J. Bull, Christine Chang, Peter H. Crackett, Gauri Deshmukh, Hazel J. Dyke, Rina Fong, Nico Ghilardi, Paul Gibbons, Peter R. Hewitt, Adam Johnson, Tony Johnson, Jane R. Kenny, Pawan Bir Kohli, Janusz J. Kulagowski, Marya Liimatta, Patrick J. Lupardus, Robert J. Maxey, Rohan Mendonca, Raman Narukulla, Rebecca Pulk, Savita Ubhayakar, Anne van Abbema, Stuart I. Ward, Bohdan Waszkowycz & Mark Zak. (2013) Novel triazolo-pyrrolopyridines as inhibitors of Janus kinase 1. Bioorganic & Medicinal Chemistry Letters 23:12, pages 3592-3598.
Crossref
Crossref
MICHAEL SKYNNER, PHIL JEFFREY, MICHAEL BINKS & MICHAEL WOODROW. 2012. Anti-Inflammatory Drug Discovery. Anti-Inflammatory Drug Discovery
211
254
.
Anthony D. William, Angeline C.-H. Lee, Anders Poulsen, Kee Chuan Goh, Babita Madan, Stefan Hart, Evelyn Tan, Haishan Wang, Harish Nagaraj, Dizhong Chen, Chai Ping Lee, Eric T. Sun, Ramesh Jayaraman, Mohammad Khalid Pasha, Kantharaj Ethirajulu, Jeanette M. Wood & Brian W. Dymock. (2012)
Discovery of the Macrocycle (9
E
)-15-(2-(Pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a Potent Inhibitor of Janus Kinase 2/Fms-LikeTyrosine Kinase-3 (JAK2/FLT3) for the Treatment of Rheumatoid Arthritis
. Journal of Medicinal Chemistry 55:6, pages 2623-2640.
Crossref
Crossref
Oliver Weigert, Andrew A. Lane, Liat Bird, Nadja Kopp, Bjoern Chapuy, Diederik van Bodegom, Angela V. Toms, Sachie Marubayashi, Amanda L. Christie, Michael McKeown, Ronald M. Paranal, James E. Bradner, Akinori Yoda, Christoph Gaul, Eric Vangrevelinghe, Vincent Romanet, Masato Murakami, Ralph Tiedt, Nicolas Ebel, Emeline Evrot, Alain De Pover, Catherine H. Régnier, Dirk Erdmann, Francesco Hofmann, Michael J. Eck, Stephen E. Sallan, Ross L. Levine, Andrew L. Kung, Fabienne Baffert, Thomas Radimerski & David M. Weinstock. (2012) Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. Journal of Experimental Medicine 209:2, pages 259-273.
Crossref
Crossref
Emilie-Fleur GautierMuriel PicardCamille LaurentCaroline MartyJean-Luc VillevalCécile DemurFrançois DelhommeauElizabeth HexnerStéphane GiraudierNicolas Bonnevialle, Bernard Ducommun, Christian RécherGuy LaurentStéphane ManentiVéronique Mansat-De Mas. (2012) The cell cycle regulator CDC25A is a target for JAK2V617F oncogene. Blood 119:5, pages 1190-1199.
Crossref
Crossref
Rebekah Baskin, Meghanath Gali, Sung O. Park, Zhizhuang Joe Zhao, György M. Keserű, Kirpal S. Bisht & Peter P. Sayeski. (2012) Identification of novel SAR properties of the Jak2 small molecule inhibitor G6: Significance of the para-hydroxyl orientation. Bioorganic & Medicinal Chemistry Letters 22:3, pages 1402-1407.
Crossref
Crossref
Linda R. Weinberg, Mark S. Albom, Thelma S. Angeles, Henry J. Breslin, Diane E. Gingrich, Zeqi Huang, Joseph G. Lisko, Jennifer L. Mason, Karen L. Milkiewicz, Tho V. Thieu, Ted L. Underiner, Gregory J. Wells, Kevin J. Wells-Knecht & Bruce D. Dorsey. (2011) 2,7-Pyrrolo[2,1-f][1,2,4]triazines as JAK2 inhibitors: Modification of target structure to minimize reactive metabolite formation. Bioorganic & Medicinal Chemistry Letters 21:24, pages 7325-7330.
Crossref
Crossref
Cui‐Juan Qian, Jun Yao & Jian‐Min Si. (2011) Nuclear JAK2: Form and Function in Cancer. The Anatomical Record 294:9, pages 1446-1459.
Crossref
Crossref
Anthony D. William, Angeline C.-H. Lee, Stéphanie Blanchard, Anders Poulsen, Ee Ling Teo, Harish Nagaraj, Evelyn Tan, Dizhong Chen, Meredith Williams, Eric T. Sun, Kee Chuan Goh, Wai Chung Ong, Siok Kun Goh, Stefan Hart, Ramesh Jayaraman, Mohammed Khalid Pasha, Kantharaj Ethirajulu, Jeanette M. Wood & Brian W. Dymock. (2011) Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma. Journal of Medicinal Chemistry 54:13, pages 4638-4658.
Crossref
Crossref
Tao Wang, Stephanos Ioannidis, Lynsie Almeida, Michael H. Block, Audrey M. Davies, Michelle L. Lamb, David A. Scott, Mei Su, Hai-Jun Zhang, Marat Alimzhanov, Geraldine Bebernitz, Kirsten Bell & Michael Zinda. (2011) In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3-carbonitriles as JAK2 kinase inhibitors. Bioorganic & Medicinal Chemistry Letters 21:10, pages 2958-2961.
Crossref
Crossref
Zohreh Hosseinzadeh, Shefalee K. Bhavsar, Mentor Sopjani, Ioana Alesutan, Ambrish Saxena, Miribane Dërmaku-Sopjani & Florian Lang. (2011) Regulation of the Glutamate Transporters by JAK2. Cellular Physiology and Biochemistry 28:4, pages 693-702.
Crossref
Crossref
Kavitha Gnanasambandan, Andrew Magis & Peter P. Sayeski. (2010) The Constitutive Activation of Jak2-V617F Is Mediated by a π Stacking Mechanism Involving Phenylalanines 595 and 617. Biochemistry 49:46, pages 9972-9984.
Crossref
Crossref